drugset / Trial / NCT07168356

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT07168356

Phase 1 Active not recruiting 32 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a 2-part study where all participants will receive bepirovirsen. The study will measure how much bepirovirsen from a single dose gets into the blood, and how long it stays in the blood. The purpose of the study is to understand if blood levels of bepirovirsen are different in adults with kidney disease compared to healthy adults who do not have kidney disease.

Timeline

Start
2025-09-26
Primary completion
2026-03-03
Completion
2026-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bepirovirsen Antisense oligonucleotide